Cargando…
The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in conjunction with the RAF inhibitor vemurafenib to treat unresectable melanoma. The addition of XL888 to current regimens may serve an additional purpose by blocking the RAF inhibitor paradox. Such activity could reduce a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568562/ https://www.ncbi.nlm.nih.gov/pubmed/26358385 http://dx.doi.org/10.1038/jid.2015.239 |